1.Abrams Е., Cardozo L., Fall M. et al. The standartization of terminology of lower urinary tract function: Report from the standartization subcommittee of the International Continence Society. Neurol. Urodyn. 2002; 21: 167-178.2.Гаджиева З.К. Нарушения мочеиспускания / Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с.3.Abrams Р., Blaivas J.G., Stanton S.L. Andersen J.T. The standardisation of terminology of lower urinary tract function recommended by International Continence Society. Int. Urogynec. J. 1990; 1: 45.4.Bates P., Glen E., Grifflths D. et al. The International Continent Commitee on standardisation and terminology (1977) - Second report on standardisation of terminology of lower urinary tract function. Scand. J. Urol. Nephrol. 11; 197-199.5.Graham C.A., Mallet V.T. Race as a predictor of urinary incontinence and pelvicoigan prolaps. Am. J. Obstet. Gynecol. 2001; 185: 116-120.6.Hannestad Y.S., Lie R. T, Rortveight G., Hanskaar S. Female urinaryincontinence - running in the family? Neurol. Urodyn. 2003; 22: 449 (abs. 60).7.Abrams Р., Artibani W., Cardozo L. et al. Clinical Manual of Incontinence in Women. New York: Healh Publications, 2005.8.MollerL.A., Lose G., Jorgensen I. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta. Obstet. Gynecol. Scand. 2000; 79: 298-305.9.Bump K.C., Norton R.A. Epidemiology and natural history of pelvic floordisoders. Obstet. Gynecol. Clin. North. Am. 1998; 25: 723-746.10.Cheater E., Castleden M. Epidemiology and classification of urinary incontinence. Baillires Best Pract. Res. Clin. Obstet. Gynecol. 2000; 14: 183-205.11.Paraztini E., Colli E., Origgy G. et al. Risk factors for urinary in continencein women. Eur. Urol. 2000; 37: 637-643.12.Bump R.C., McClish D.K. Cigarette smoking and pure genuine stress incontinence of mine: a comparison of risk factors and determinants between smokers and nonsmokers. Am. J. Obstet. Gynecol. 1994; 170: 579-582.13.Brubaker L., Bump R., Jacquetin B. Pelvic organ prolapse In: Incontinence / P. Abrams et al. Plymouth: Plymbridge Distributors Ltd, 2002. P. 243-265.14.Мазо Е.Б., Кривобородов Г.Е., Школьников M.E. Стандартизация терминологии функции нижних мочевых путей. Доклад стандартизационного подкомитета Международного общества по удержанию мочи. М., 2003.15.Abrams Р. et al. 4th International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence. 2009. P. 1767-1820.16.Xepm F. Оперативная урогинекология. M.: ГЭОТАР-Медиа, 2003. 54 с.17.Lucas М. G. et al. Guidelines on urinary incontinence. EAU pocket guidelines. 2013. P. 175-198.18.Лопаткин Н.А. Урология. Клинические рекомендации (2-е издание). М.: ГЭОТАР-Медиа, 2013. 416 с.19.http://uroweb.org/fileadmin/guidelines/Guidelines_2014_5_June_2014.pdf20.Касян R.P., Гвоздев М.Ю., Годунов Б.Н., Прокопович М.А., Пушкарь Д.Ю. Анализ результатов лечения недержания мочи у женщин с использованием свободной субуретральной синтетической петли: опыт 1000 операций. Урология. 2013; 4: 5-11.21.Pushkar D.Y., Godunov B.N., Gvozdev M., Kasyan G.R. Complications of midurethral slings for treatment of stress urinary incontinence. Int. J Gynaecol. Obstet. 2011; 113(l): 54-57.22.Пушкарь Д.Ю., Касян T.P. Отдаленные результаты использования свободной синтетической петли в лечении недержания мочи у женщин (восьмилетние результаты). Урология. 2010; 2: 32.23.Nilsson C.G., Palva K., Aamio R., Morcos E., Falconer C. Seventeen years’ follow up of the tension-free vaginal tape procedure for female stress urinary incontinence. Int Urogynecol J. 2013; 24(8): 1265-1269.24.Chappie C., Yamaguchi O., Bidder A., Liehne J., Carl S., Mattiasson A. et al. Clinical proof of concept study (Blossom) shows novel b3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol 2008; (Suppl. 7): 239.25.Chappie C., Wyndaele J., Van Kerrebroeck P., Radziszewski P., Dvorak V., Boerrigter P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur. Urol. 2010; (Suppl. 9): 249.26.Chappie C.R., Kaplan SA., Mitcheson D. et al. Randomized double-blind, active- controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63(2): 296-305.